Breaks Categories: Analyst Alerts

WednesdayMay 17, 2017 11:10 am

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $3 on Ocera Therapeutics (NASDAQ: OCRX) following the company’s recent report of financial results for the quarter ended March 31, 2017. Ocera reported cash, cash equivalents and marketable securities of $25.2 million and restated prior guidance of cash on hand supporting operations into the second quarter of 2018. The company also provided an update on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE). The company is expected to have an end of phase 2 meeting with the FDA in the third quarter of 2017, which…

Continue Reading

WednesdayMay 17, 2017 11:08 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital has reiterated a ‘Buy’ rating and a price target of $25 on Akebia Therapeutics (NASDAQ: AKBA) following the company’s recent report of financial results for the first quarter ended March 31, 2017. Akebia reported cash, cash equivalents and marketable securities of $251.8 million. Combined with additional upcoming payments, the company said it expects to have resources to fund the current operating plan into the first quarter of 2019. Among other highlights, the analyst noted Akebia’s upcoming milestones, including the top-line results of a phase 2 trial in Japan in the second half of 2017; the initiation of a…

Continue Reading

MondayMay 15, 2017 12:18 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Nektar Therapeutics (NASDAQ: NKTR)

Following the release of Nektar Therapeutics’ (NASDAQ: NKTR) first-quarter results, Aegis Capital reiterated its ‘Buy’ rating and price target of $27 on shares of the company’s stock. Though Nektar’s first-quarter revenue of $24.7 million fell short of the consensus of $30.9 million, the Aegis analyst noted the company’s multiple product candidates awaiting approval and potential upcoming product launches as the area of focus. Additionally, Nektar recently reported positive top-line data for the phase 3 Summit-07 trial evaluating NKTR-181 in chronic lower back pain. Readout for the ongoing pivotal trial is anticipated in mid-summer 2017. For more information, visit www.nektar.com About Nektar…

Continue Reading

MondayMay 15, 2017 12:16 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) following release of the company’s first-quarter results. Revance reported cash and investments of $188.6 million as of March 31, 2017, which the analyst noted is expected to support operations through year end 2018. The company also provided a clinical development update, including news that the Sakura 1 & 2 phase 3 trials for glabellar lines are on track to report top-line results in the fourth quarter of 2017. Additionally, the company’s phase 2 trial for plantar fasciitis is set to report top-line…

Continue Reading

FridayMay 12, 2017 11:08 am

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Has “Buy” Rating Reiterated by Aegis Capital

Trevena (NASDAQ: TRVN) is reiterated with a ‘Buy’ rating and $14 price target by Aegis Capital Corp. following the biopharmaceutical company’s report of financial results for the quarter ended March 31, 2017. Trevena reported cash, cash equivalents, and marketable securities at $97.9 million as of March 31, 2017. Trevena expects its cash on hand will fund operations into the third quarter of 2018. This includes funding enrollment in the phase 3 ATHENA study by mid-year adequate to support the submission of the NDA for OLINVO, submitting the NDA to the FDA in the fourth quarter of 2017, advancing TRV250 through…

Continue Reading

FridayMay 12, 2017 11:06 am

NetworkNewsBreaks – Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) Receives Reiterated “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and a price target of $11 on shares of Conatus Pharmaceuticals (NASDAQ: CNAT) after the company reported first quarter 2017 financial results. The company reported total revenues of $7.0 million and cash, cash equivalents and marketable securities of $80.5 million at the end of the first quarter. Among other highlights, the analyst noted that the company said Novartis has exercised its exclusive license option for the global development and commercialization of emricasan, which will become effective after Conatus receives a $7 million payment from Novartis. The payment is expected in mid-2017. For more information,…

Continue Reading

ThursdayMay 11, 2017 12:53 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Zogenix, Inc. (NASDAQ: ZGNX)

Following Zogenix’s (NASDAQ: ZGNX) first-quarter results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of the company’s stock. Zogenix reported total revenue for the first quarter of $2.7 million, consisting entirely of contract manufacturing revenue. Additionally, Zogenix recently said it has completed enrollment in Study 1, the first phase 3 clinical trial evaluating ZX008 as an adjunctive treatment for seizures in children and young adults with Dravet syndrome. Top-line data from Study 1 is anticipated in the third quarter of 2017. The company is currently enrolling for 1504, the second pivotal phase 3 trial in…

Continue Reading

ThursdayMay 11, 2017 12:52 pm

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating on CytoSorbents Corp. (NASDAQ: CTSO)

Aegis Capital has issued a ‘Buy’ rating and price target of $9 on CytoSorbents Corp. (NASDAQ: CTSO) following the company’s report of financial and operational results for the quarter ended March 31, 2017. The company reported total revenues of $3.1 million for the first quarter of 2017, which includes both product sales and grant income. This represents an increase of 72% from revenues of $1.8 million from the same period of the previous year. The analyst noted the company’s plan to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval of its flagship CytoSorb® blood filter as well as plans to expand…

Continue Reading

WednesdayMay 10, 2017 12:49 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on Recro Pharma, Inc. (NASDAQ: REPH)

Aegis Capital has issued a ‘Buy’ rating and price target of $11 on Recro Pharma (NASDAQ: REPH) following the company’s recent report of positive top-line results from its phase 3 safety study evaluating intravenous (IV) meloxicam following major surgery. The analyst noted that the final clinical requirement was met for the IV Meloxicam NDA, and the company is on track to file in the third quarter of 2017. Shares of Recro Pharma are currently trading at $7.57 with a 52-week range of $0.59-$12.50. For more information, visit www.recropharma.com About Recro Pharma, Inc. Recro is a specialty pharmaceutical company that operates…

Continue Reading

WednesdayMay 10, 2017 12:47 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating on Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is…

Continue Reading